Grants for Unrestricted - Federal

Request for Information/Sources Sought Notice-Countering Violent Extremism in Northeast Syria Among the YouthThis Request for Information (RFI) seeks insights on effective strategies to combat violent extremism, particularly among youth, in non-regime areas of Syria with a particular focus on the northeast (NES). The questions included in Attachment 1 aim to gather information on factors contributing to youth vulnerability to violent extremism. Additionally, the RFI seeks to explore potential partnerships and strategies to engage local communities, public institutions, and the private sector in building youth resilience against extremist messaging and recruitment efforts.By understanding these dynamics, USAID/Syria aims to develop comprehensive, community-driven approaches to prevent youth radicalization and support sustainable peace in the region.

This funding opportunity is designed for research institutions affiliated with the Pacific Northwest Cooperative Ecosystem Studies Unit to investigate the impact of stormwater runoff on salmon, focusing on the bioaccumulation and toxicity of specific organic chemicals.

Dear Prospective Applicants: The United States Agency for International Development (USAID) is seeking applications for a Cooperative Agreement from qualified entities to implement the above-mentioned Program outlined in the subject NOFO. Eligibility for this award is not restricted. USAID intends to make a single award to the applicant(s) who best meets the objectives of this funding opportunity based on the merit review criteria described in this NOFO subject to a risk assessment. Eligible entities interested in submitting an application are encouraged to read this NOFO thoroughly to understand the type of activity sought, application submission requirements, and selection process. Subject to funding availability, USAID intends to provide up to $13,000,000.00 in total USAID funding to the USAID The Gambia Malaria Elimination Activity (GMEA or activity). To be eligible for award, the applicant must provide all information as required in this NOFO and meet eligibility standards in Section C of this NOFO. This funding opportunity is posted on www.grants.gov, and may be amended. It is the responsibility of the applicant to regularly check the website to ensure they have the latest information pertaining to this notice of funding opportunity and to ensure that the NOFO has been received from the internet in its entirety. USAID bears no responsibility for data errors resulting from transmission or conversion process. If you have difficulty registering on www.grants.gov or accessing the NOFO, please contact the Grants.gov Helpdesk at 1-800-518-4726 or via email at support@grants.gov for technical Assistance. USAID may not award to an applicant unless the applicant has complied with all applicable unique entity identifier and System for Award Management (SAM) requirements detailed in Section D.6.g. The registration process may take many weeks to complete. Therefore, applicants are encouraged to begin registration early in the process. Please send any questions to the point(s) of contact identified in Section G. The deadline for questions is shown above. Responses to questions received prior to the deadline will be furnished to all potential applicants through an amendment to this notice posted to www.grants.gov. Issuance of this notice of funding opportunity does not constitute an award commitment on the part of the Government nor does it commit the Government to pay for any costs incurred in preparation or submission of comments/suggestions or an application. Applications are submitted at the risk of the applicant. All preparation and submission costs are at the applicants expense. Please note that USAID reserves the right to cancel this process at any time without prior notice. Thank you for your interest in USAID programs.` Sincerely,

This funding opportunity supports clinical trials that seek to improve the prevention, treatment, or management of health issues related to toxic exposures experienced by military personnel.

This initiative seeks input from organizations with expertise in agricultural water management and climate adaptation to help improve irrigation and water resource management for smallholder farmers in Guatemala.

This funding opportunity provides financial support to local organizations in El Salvador, Guatemala, and Honduras to lead initiatives that promote economic growth, education, citizen security, and governance, prioritizing community-driven solutions and inclusivity.

This funding opportunity is designed to support projects that enhance ocean, coastal, and Great Lakes observations and data dissemination to improve safety, economic development, and environmental protection across the United States.

This grant seeks innovative ideas from researchers, companies, and academic institutions to explore and develop environmentally sustainable methods for discovering and assessing natural hydrogen resources underground.

The TrDA is intended to improve diagnosis now. Proposed projects must build knowledge, capacity, technology, and/or research to reduce or overcome important barriers to obtaining a diagnosis, meaningful disease monitoring, and accurate prognosis. Barriers could include, but are not limited to, technologies, cost, equitable patient access, applicability, structural and social determinants of health, clinical implementation, relationship to clinical outcome measures, biomarker validation, lack of longitudinal data to inform prediction/prognosis, and more. The investigator must clearly attune their project to provide true benefit to people living with AD/ADRD diagnoses and their families. All applications submitted to this funding opportunity must clearly indicate how the project addresses an important barrier, explain how the research will be representative of the population it intends to benefit, and demonstrate cultural competence. Culturally competent research factors the cultural background and diversity of the intended beneficiaries of the research outcomes when developing research ideas, conducting research, and implementing the research findings. Cultural competency in research is critical in reducing health disparities and enhancing the quality and impact of research by ensuring inclusivity, understanding, and responsiveness to the needs of diverse populations.Key elements of this award mechanism are: Clear pathway to applicability: To meet the intent of this mechanism, applications should be focused on a clear pathway to clinical applicability. Proposed projects should identify and begin to address gaps limiting advances in equitable, accessible, and rapid diagnosis and/or prognosis. Gaps may include but are not limited to technologies, state of the science, health equity, biomarker applicability, and more. Applications that do not clearly delineate how the proposed project addresses and/or overcomes barriers to accessible and viable diagnosis and/or prognosis do not meet the intent of this mechanism. Non-incremental advance: Proposed research should demonstrate an appreciable advance on the current state of the field. As such, preliminary data are required. Person-focused research: For diagnostic/prognostic outcomes proposed by the research to be successful, those impacted by AD/ADRD diagnoses need to buy into the approach. This means researchers should design their projects to focus on the people who need the outcomes most and partner with them. For the FY24 PRARP TrDA, inclusion of Community collaboration is required for all projects.The proposed project should leverage existing resources, where possible, and must ensure the advances proposed by the project aims are representative and applicable to diverse populations, especially including women. Careful consideration of equitable, representative inclusion of the study populations is essential to ensuring AD/ADRD diagnostic or prognostic solutions are of benefit to all and that this is a high priority for the program.For this mechanism, the investigator will host a Community meeting with a facilitated discussion, to occur within the first three quarters of the period of performance, that will help inform the execution of the research. This meeting should involve the intended research population and their Community. The intent of this meeting is to gather feedback and input that will inform the execution of the research, optimize and refine research questions and execution as well as help inform the dissemination strategy of the research outcomes. Optimizing research impact through Community collaboration: Research funded by the FY24 PRARP should be responsive to the needs of persons with AD/ADRD lived experience, family, and/or care provider communities (referred to as Community/ies from hereon in the Funding Opportunity). Establishment and utilization of effective and equitable collaborations and partnerships maximizes the near-term translational and impact potential of the proposed research. Collaborative research approaches feature shared responsibility and ownership for the research project to ensure fully integrated involvement of Community members within the research team. Collaborative research approaches such as Community-based participatory research, participatory action research, and integrated knowledge transition generate partnerships between scientific researchers and Community members to create knowledge useable by both sets of stakeholders. Recognizing the strengths of each partner, scientific researchers and Community members must collaborate and contribute their expertise equitably on all aspects of the project, which may include needs assessment, planning, research intervention design, implementation, evaluation, and dissemination. Research results are jointly interpreted, disseminated, fed back to affected communities, and may be translated into interventions or policy. These methods are critically important for Community-level interventions and can also augment the potential impact of a research program on people living with dementia, their families, and/or their care partners.These collaborative relationships are often established through integrating Community members into research teams as co-researchers, advisors, and consultants. Some examples for Community collaborations include: o Lived Experience Consultation: The research team includes at least one project advisor with AD/ADRD experience who will integrate with the research team to provide consultation throughout the planning, implementation, and dissemination of the research project. Lived experience consultants (LECs) may include individuals with AD/ADRD, their family members, care partners/caregivers, or others as appropriate.o Partnership with a Community-Based Organization: The research team establishes partnerships with at least one Community-based organization that provides consultation throughout the planning, implementation, and dissemination of the research project. Community-based organizations may include advocacy groups, service providers, policymakers, or other formal organizational stakeholders.o Community Advisory Board (CAB): A CAB is composed of multiple Community stakeholders and can take many forms, from a board of LECs to a coalition of Community-based organizations or any combination thereof. As with LECs and organizational partners, the CAB provides consultation throughout the planning, implementation, and dissemination of the research project.

The purpose of this Amendment is to provide answers to the questions submitted by the interested applicants, and to provide specific changes that were made to the original RFA . All changes in the amended RFA are highlighted for ease of reference.Thank you for your interest in USAID programs.

This funding opportunity is designed for organizations already involved in a specific cooperative agreement to enhance training programs for managing individuals in restrictive housing environments within correctional facilities.

This funding opportunity provides financial support for community organizations and local governments to develop and implement workforce training and employment programs that address regional labor market needs.

The 24.PMWRA.PapuaNewGuinea.UXO.NOFO grant is a funding opportunity from the U.S. Department of State, offering up to $2,250,000 for organizations to establish operations for unexploded ordnance and humanitarian mine action in Papua New Guinea in 2025.

This funding opportunity is designed for research partners within the Chesapeake Watershed Cooperative Ecosystem Studies Unit to study and address ecological changes in salt marshes impacted by sea level rise and other environmental factors.

The purpose of the new RLG activity is to support LEGI in improving its planning and responsiveness to the concerns and public and private service delivery needs of their communities, making sure no group is excluded. With the new LG activity, USAID will support an inclusive and localized approach to ensure citizen accountability. Activity Goal: More effective and responsive local governance and practices. Activity Objective: To develop LEGIs as an effective, responsive, inclusive, and accountable institution to address social issues and provide quality basic services to the most marginalized. Intermediate Result-1: Strengthened LEGI capacity to be more transparent and accountable to the community and to monitor the quality of public and private services: Under this IR, the RLG activity will develop tools and practices that enable local systems to become more accountable, gender-sensitive, effective, and responsive institutions. For sustainability, RLG will work closely with the National Institution of Local Government (NILG) to incorporate successful training interventions in their curriculum (more will be explored in the LG Assessment for sustainability). Under this IR, the activity will support policy advocacy by LEGIs to encourage the national government to adopt legal and policy reforms to expand roles, authorities, and resource allocations for local governments so that they can improve service delivery by the cognizant offices. RLG will make efforts to promote e-governance practices within the LEGI and also to make them instrumental for overall e-governance practices at the community level. Through this IR, USAID intends to work with relevant local government actors to refine and institutionalize participatory practices in annual planning and budgeting for their areas. Intermediate Result-2: Improved civil society, community-based organization, and citizen participation in local decision-making and in monitoring public service delivery, including those contracted out to the private sector: This IR will work on citizen participation in local decision-making by developing Citizens Forums, including training and technical assistance to enhance the forums ability to play an effective and active role in public management oversight. The training will include immediate and ongoing opportunities over an extended period of time for participants to practice and apply their new knowledge, skills, and tools to their participation in local governance, with accompanying coaching by the RLG activity. The LG Assessment will explore existing Citizen Forums at the community level and recommend if those can be included in the RLG activity. Through the existing forums or new forums, the activity will prepare the community to participate in the annual planning and budget session and at the same time strengthen their advocacy capacity for better services. Illustrative interventions: Intermediate Result-3: Strengthened LEGI-private-sector-civil society organization (CSO) coordination to improve the quality of public and private services: Coordination among central government (both field administration and service delivery offices), CSOs and the LEGIs are crucial to ensure optimal governance at the local level. Recent studies[1] indicate that NGOs have crucial roles in improving local governance, especially during the post-pandemic era. Both LEGIs and CSOs/CBOs work very closely with citizens and, with support, can form a tight alliance to advocate for better services for the community. In doing so, this activity will strongly encourage civil society and LEGI to partner with the private sector for improving service delivery.

This program provides funding to organizations and researchers focused on improving the quality and diversity of medical imaging data to develop reliable AI tools for faster and more accurate healthcare diagnostics.

This initiative seeks input from industry stakeholders, researchers, and government entities to explore the potential and challenges of integrating photovoltaic-thermal systems in the U.S. energy market.

The United States Agency for International Developments Mission to Vietnam (USAID/Vietnam) is in the process of gathering information to support the anticipated Innovative Workforce Activity. This potential five-year award will aim to enhance the capacity of Vietnams digital workforce and local innovation to meet the demands of a growing digital economy and support the realization of Vietnams National Strategy on the Industrial Revolution - 4.0.The purpose of this Request for Information (RFI) is to conduct market research and to obtain input from interested parties. USAID welcomes any information and any relevant general feedback and comments that partners may wish to share. Attachment 1 below includes a draft activity description. Attachment 2 contains specific questions and response submission guidelines.

The Civil Society Resilience (CSR) Activity aims to improve Cambodias civil society and grassroots organizers to be more effective while maintaining civil societys ability to function within the countrys closing civic space. The Activity will address the needs, opportunities, and challenges identified by the civic actors, across relevant sectors, to foster engagement and respond to civic space challenges. The CSR activity will strengthen the agency, resiliency, and efficacy of civil society to advance agendas that are in the public interest and advance inclusive development. This CSR Activity contains the following three objectives: Objective 1: Provide flexible financial and technical support available to bolster the agency and resilience of civil society and grassroots organizers, across sectors. Objective 2: Promote practices that strengthen strategic decision-making, resource mobilization, coordination, communication, and long-term planning to advance reforms. Objective 3: Strengthen access to learning, networking, and exchange opportunities that civil society identifies as central to the success of their work.

Maturing research ideas into clinical practice and patient benefit is at the heart of all CDMRP research programs. Despite significant investment, the gap between what is possible and what is achieved remains. Even after information, tools, and interventions have been successfully evaluated in their intended populations, the development of knowledge to support their broader dissemination and implementation has often remained outside the scope of previous clinically focused award mechanisms.The FY24 MBRP PCRA intends to bridge the gap between research, practice, and policy by building a knowledge base that provides clinically useful findings about how interventions, clinical practices/guidelines, tools, and policies can be deployed to targeted populations at the appropriate time at the point of need. Funding from this award mechanism must support clinical research or clinical trials but cannot be used for preclinical or animal research. Applications may propose prospective or retrospective research involving human subjects, human subject data/records, and human anatomical substances.The FY24 PCRA may support studies focusing on the following (not all inclusive): Research that accelerates the uptake and implementation of evidence-based research into clinical practice Comparative effectiveness research comparing the benefits and harms of emerging or established interventions and strategies to prevent, diagnose, treat, and monitor health conditions in real-world settings Development and evaluation of strategies to overcome barriers to the adoption, adaptation, integration, scale-up, and sustainability of evidence-based interventions, tools, policies, and guidelines Analysis of existing clinical data or clinical data resources to inform clinical practice Modification of established clinical tools for their intended population or environment Analysis of existing clinical tools to maximize patient-relevant outcomes Identification and analysis of the circumstances that create a need to stop or reduce (de-implement) the use of interventions, tools, policies, and guidelines that are ineffective, unproven, low-value, or harmful Analysis of burn outcomes associated with the implementation of clinical practice guidelines, evidence-based practices, and process improvements The following are important aspects of the FY24 MBRP PCRA: Precision Medicine Approaches: When appropriate, the MBRP encourages the use of precision medicine approaches. These tailored treatments deliver the right treatment at the right time while considering an individuals unique characteristics. Preliminary data are required: Inclusion of preliminary data relevant to the proposed clinical research/trial is required. Study Population: The application should demonstrate the availability of and access to a suitable patient population that will support a meaningful outcome for the study. The application should include a discussion of how accrual goals will be achieved, as well as the strategy for inclusion of women and minorities in the clinical trial appropriate to the objectives of the study. Studies utilizing human biospecimens or datasets that cannot be linked to a specific individual, gender, ethnicity, or race (typically classified as exempt from Institutional Review Board [IRB] review) are exempt from this requirement. Clinical Trial Start Date: If applicable, the proposed clinical trial is expected to begin no later than 6 months after the award date. Intervention Availability: If applicable, the application should demonstrate the documented availability of and access to the drug/compound, device, and/or other materials needed, as appropriate, for the proposed duration of the study.Rigor of Experimental Design: All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of clinical and preclinical research. The standards are described in SC Landis et al., 2012, A call for transparent reporting to optimize the predictive value of preclinical research, Nature 490:187-191 (http://www.nature.com/nature/journal/v490/n7419/full/nature11556.html). While these standards are written for preclinical studies, the basic principles of randomization, blinding, sample-size estimation, and data handling derive from well-established best practices in clinical studies.Applications involving multidisciplinary collaborations among academia, industry, the military Services, the U.S. Department of Veterans Affairs (VA), and other federal government agencies are highly encouraged. These relationships can leverage knowledge, infrastructure, and access to unique clinical populations that the collaborators bring to the research effort, ultimately advancing research that is of significance to Service Members, Veterans, and/or their Families. If the proposed research relies on access to unique resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research.A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research. Clinical research encompasses research with human data, human specimens, and/or interaction with human subjects. Clinical research is observational in nature and includes:(1) Research conducted with human subjects and/or material of human origin such as data, specimens, and cognitive phenomena for which an investigator (or co-investigator) does not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. Research meeting this definition may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies.(2) Epidemiologic and behavioral studies that do not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention.(3) Outcomes research and health services research that do not fit under the definition of clinical trial.Excluded from the definition of clinical research are in vitro studies that utilize human data or specimens that cannot be linked to a living individual and meet the requirements for exemption under 46.104(d)(4) of the Common Rule.Impact: The overall impact of the proposed research is a key component of this award mechanism. High-impact research will, if successful, lead to the clinical implementation of therapeutics, technologies, or clinical practice guidelines that advance the care of burn-injured casualties.Relevance to Military Health: Relevance to the health care needs of burn-injured military Service Members is a key feature of this award.Use of DOD or VA Resources: If the proposed research involves access to active-duty military and/or VA patient populations and/or DOD or VA resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research. Refer to Section II.D.2.b.ii, Full Application Submission Components, for detailed information. Refer to the General Application Instructions, Appendix 1, for additional information.Applicants are encouraged to integrate and/or align their research projects with DOD and/or VA research laboratories and programs. Collaboration with DOD or VA investigators is also encouraged. A list of websites that may be useful in identifying additional information about ongoing DOD and VA areas of research interest or potential opportunities for collaboration can be found in Appendix 2.Research Involving Human Anatomical Substances, Human Subjects, or Human Cadavers: All DOD-funded research involving new and ongoing research with human data,human anatomical substances, human subjects, or human cadavers must be reviewed and approved by the USAMRDC Office of Human and Animal Research Oversight (OHARO), Office of Human Research Oversight (OHRO), prior to research implementation. This administrative review requirement is in addition to the local IRB or Ethics Committee (EC) review. Local IRB/EC approval at the time of application submission is not required; however, local IRB/EC approval is necessary prior to OHRO review. Allow up to 3 months to complete the OHRO regulatory review and approval process following submission of all required and complete documents to the OHRO. Refer to the General Application Instructions, Appendix 1, and the OHARO web pagehttps://mrdc.health.mil/index.cfm/collaborate/research_protections for additional information.If the proposed research involves more than one institution, a written plan for single IRB review arrangements must be provided at the time of application submission or award negotiation. The lead institution responsible for developing the master protocol and master consent form should be identified and should be the single point of contact for regulatory submissions and requirements.The types of awards made under the program announcement will be assistance agreements. An assistance agreement can take the form of a grant or cooperative agreement. The level of government involvement during the projects period of performance is the key factor in determining whether to award a grant or cooperative agreement. If no substantial government involvement is anticipated, a grant will be made (31 USC 6304). Conversely, if substantial government involvement is anticipated, a cooperative agreement will be made (31 USC 6305). Substantial involvement means that members of the U.S. government will assist, guide, coordinate, or participate in project activities.The award type, along with the start date, will be determined during the negotiation process.The anticipated total costs budgeted for the entire period of performance for an FY24 MBRP Patient-Centered Research Award should not exceed $2.2M. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.Awards supported with FY24 funds will be made no later than September 30, 2025.The CDMRP expects to allot approximately $4.4M to fund approximately two Patient-Centered Research Award applications. Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY24 funding opportunity will be funded with FY24 funds, which will expire for use on September 30, 2030.